Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Kazuhiko Hoshino"'
Autor:
Ikuro Matsuba, Kotaro Iemitsu, Takehiro Kawata, Takashi Iizuka, Masahiro Takihata, Masahiko Takai, Shigeru Nakajima, Nobuaki Minami, Shinichi Umezawa, Akira Kanamori, Hiroshi Takeda, Shogo Ito, Taisuke Kikuchi, Hikaru Amemiya, Mizuki Kaneshiro, Atsuko Mokubo, Tetsuro Takuma, Hideo Machimura, Keiji Tanaka, Taro Asakura, Akira Kubota, Sachio Aoyagi, Kazuhiko Hoshino, Masashi Ishikawa, Mitsuo Obana, Nobuo Sasai, Hideaki Kaneshige, Masaaki Miyakawa, Yasushi Tanaka, Yasuo Terauchi
Publikováno v:
Journal of Endocrinology and Metabolism. 9:151-158
Autor:
Nobuo Sasai, Tetsuya Motomiya, Kotaro Iemitsu, Hajime Maeda, Atsuko Mokubo, Hikaru Amemiya, Hiroshi Takeda, Akira Kanamori, Tomoyuki Iwasaki, Takehiro Kawata, Hideaki Kaneshige, Takashi Iizuka, Fuyuki Minagawa, Masashi Ishikawa, Goro Uehara, Mizuki Kaneshiro, Yasushi Tanaka, Tatsuya Saito, Keiji Tanaka, Yasuo Terauchi, Ikuro Matsuba, Nobuaki Minami, Hideo Machimura, Shin Honda, Shigeru Nakajima, Mitsuo Obana, Masaaki Miyakawa, Yukiko Miyairi, Kazuhiko Hoshino, Masahiko Takai, Manabu Waseda, Akira Kubota, Kiyokazu Matoba, Tetsuo Takuma, Shinichi Umezawa
Publikováno v:
Journal of Clinical Medicine Research
Background: Sitagliptin, the first dipeptidyl peptidase-4 inhibitor, has demonstrated efficacy and safety as monotherapy and as add-on therapy to oral antidiabetic agents or insulin. However, there have been few reports about sitagliptin in elderly p
Autor:
Kotaro Iemitsu, Takehiro Kawata, Takashi Iizuka, Masahiro Takihata, Masahiko Takai, Shigeru Nakajima, Nobuaki Minami, Shinichi Umezawa, Akira Kanamori, Hiroshi Takeda, Shogo Ito, Taisuke Kikuchi, Hikaru Amemiya, Mizuki Kaneshiro, Atsuko Mokubo, Tetsuo Takuma, Hideo Machimura, Keiji Tanaka, Taro Asakura, Akira Kubota, Sachio Aoyagi, Kazuhiko Hoshino, Masashi Ishikawa, Yoko Matsuzawa, Mitsuo Obana, Nobuo Sasai, Hideaki Kaneshige, Fuyuki Minagawa, Tatsuya Saito, Kazuaki Shinoda, Masaaki Miyakawa, Yasushi Tanaka, Yasuo Terauchi, Ikuro Matsuba
Publikováno v:
Journal of Endocrinology and Metabolism. 9:51-62
Autor:
Masashi Ishikawa, Masahiko Takai, Hajime Maeda, Akira Kanamori, Akira Kubota, Hikaru Amemiya, Takashi Iizuka, Kotaro Iemitsu, Tomoyuki Iwasaki, Goro Uehara, Shinichi Umezawa, Mitsuo Obana, Hideaki Kaneshige, Mizuki Kaneshiro, Takehiro Kawata, Nobuo Sasai, Tatsuya Saito, Tetsuo Takuma, Hiroshi Takeda, Keiji Tanaka, Shigeru Nakajima, Kazuhiko Hoshino, Shin Honda, Hideo Machimura, Kiyokazu Matoba, Fuyuki Minagawa, Nobuaki Minami, Yukiko Miyairi, Atsuko Mokubo, Tetsuya Motomiya, Manabu Waseda, Masaaki Miyakawa, Yasuo Terauchi, Yasushi Tanaka, Ikuro Matsuba
Publikováno v:
Journal of Endocrinology and Metabolism. 8:126-138
Autor:
Nobuaki Minami, Shigeru Nakajima, Sachio Aoyanagi, Atsuko Mokubo, Masashi Ishikawa, Masahiro Takihata, Yasushi Tanaka, Takehiro Kawata, Kotaro Iemitsu, Takashi Iizuka, Ikuro Matsuba, Akira Kanamori, Akira Kubota, Kazuaki Shinoda, Taisuke Kikuchi, Mizuki Kaneshiro, Tatsuya Saito, Kazuhiko Hoshino, Keiji Tanaka, Nobuo Sasai, Mitsuo Obana, Masahiko Takai, Hikaru Amemiya, Hideaki Kaneshige, Yoko Matsuzawa, Hiroshi Takeda, Hideo Machimura, Yasuo Terauchi, Taro Asakura, Fuyuki Minagawa, Shinichi Umezawa, Tetsuo Takuma, Masaaki Miyakawa, Shogo Ito
Publikováno v:
Journal of Clinical Medicine Research
Background: Ipragliflozin is a selective sodium glucose co-transporter 2 inhibitor. The ASSIGN-K study is investigating the efficacy and safety of ipragliflozin for type 2 diabetes mellitus (T2DM) in the real-world clinical setting. Methods: Japanese
Autor:
Yasushi Tanaka, Ikuro Matsuba, Atsuko Mokubo, Sachio Aoyanagi, Yasuo Terauchi, Hikaru Amemiya, Hiroshi Takeda, Akira Kanamori, Nobuaki Minami, Akira Kubota, Hideaki Kaneshige, Shigeru Nakajima, Yoko Matsuzawa, Hideo Machimura, Kazuaki Shinoda, Takehiro Kawata, Takashi Iizuka, Tatsuya Saito, Mizuki Kaneshiro, Masahiko Takai, Keiji Tanaka, Taro Asakura, Masahiro Takihata, Fuyuki Minagawa, Mitsuo Obana, Masashi Ishikawa, Taisuke Kikuchi, Kazuhiko Hoshino, Kotaro Iemitsu, Nobuo Sasai, Shinichi Umezawa, Shogo Ito, Tetsuo Takuma, Masaaki Miyakawa
Publikováno v:
Journal of Clinical Medicine Research
Background: Ipragliflozin, a sodium-glucose transporter 2 inhibitor, was administered to patients with type 2 diabetes mellitus for 24 weeks to evaluate its effect on glycemic control and body composition. Methods: This was an investigator-initiated
Autor:
Takehiro Kawata, Takashi Iizuka, Taro Asakura, Fuyuki Minagawa, Hideo Machimura, Nobuo Sasai, Mizuki Kaneshiro, Akira Kanamori, Keiji Tanaka, Akira Kubota, Masaaki Miyakawa, Nobuaki Minami, Shigeru Nakajima, Taisuke Kikuchi, Shogo Ito, Hiroshi Takeda, Kazuaki Shinoda, Kotaro Iemitsu, Yasushi Tanaka, Yasuo Terauchi, Hikaru Amemiya, Masahiko Takai, Hideaki Kaneshige, Tatsuya Saito, Ikuro Matsuba, Yoko Matsuzawa, Mitsuo Obana, Sachio Aoyagi, Kazuhiko Hoshino, Masahiro Takihata, Atsuko Mokubo, Masashi Ishikawa, Shinichi Umezawa, Tetsuo Takuma
Publikováno v:
Journal of Clinical Medicine Research
Background: Ipragliflozin is a sodium-glucose co-transporter 2 inhibitor that can improve glycemic control and reduce body weight and blood pressure in patients with type 2 diabetes mellitus (T2DM). We evaluated the efficacy and safety of ipraglifloz
Autor:
Nobuaki Minami, Shigeru Nakajima, Akira Kubota, Nobuo Sasai, Tomoyuki Iwasaki, Yukiko Miyairi, Hiroshi Takeda, Yasushi Tanaka, Shinichi Umezawa, Yasuo Terauchi, Ikuro Matsuba, Nobuaki Tsurui, Mitsuo Obana, Masaaki Miyakawa, Yoshikazu Naka, Masashi Ishikawa, Kiyokazu Matoba, Masahiko Takai, Atsuko Mokubo, Hikaru Amemiya, Tatsuya Saito, Manabu Waseda, Akira Kanamori, Hideaki Kaneshige, Tetsuya Motomiya, Shin Honda, Fuyuki Minagawa, Hideo Machimura, Tetsuo Takuma, Mizuki Kaneshiro, Takehiro Kawata, Kazuhiko Hoshino, Goro Uehara, Kotaro Iemitsu, Keiji Tanaka, Takashi Iizuka, Hajime Maeda
Publikováno v:
Journal of Clinical Medicine Research
Background: It is unclear whether dipeptidyl peptidase-4 inhibitors decrease hemoglobin A 1c (HbA 1c ) in a glucose-dependent manner in patients on insulin therapy who have impaired insulin secretion. This study investigated factors influencing the e
Autor:
Akira Kanamori, Taro Asakura, Masahiko Takai, Masashi Ishikawa, Yasushi Tanaka, Nobuaki Minami, Akira Kubota, Nobuo Sasai, Hideo Machimura, Shigeru Nakajima, Ikuro Matsuba, Masaaki Miyakawa, Yasuo Terauchi, Hikaru Amemiya, Mizuki Kaneshiro, Kazuhiko Hoshino, Hideaki Kaneshige, Hiroshi Takeda, Tetsuro Takuma, Keiji Tanaka, Shinichi Umezawa, Kotaro Iemitsu, Sachio Aoyagi, Atsuko Mokubo, Shogo Ito, Mitsuo Obana, Taisuke Kikuchi, Takehiro Kawata, Takashi Iizuka, Masahiro Takihata
Publikováno v:
Journal of Clinical Medicine Research
Background: Ipragliflozin is a selective sodium glucose co-transporter 2 (SGLT2) inhibitor that blocks glucose reabsorption in the proximal tubules. SGLT2 inhibitors are expected to be effective in patients with insulin resistance and obesity, but it
Autor:
Hajime Maeda, Yasushi Tanaka, Masashi Ishikawa, Shin Honda, Tetsuya Motomiya, Ikuro Matsuba, Takehiro Kawata, Hideo Machimura, Kotaro Iemitsu, Atsuko Mokubo, Tetsuro Takuma, Hideaki Kaneshige, Akira Kanamori, Yasuyuki Jin, Kazuhiko Hoshino, Nobuaki Minami, Yasuo Terauchi, Mizuki Kaneshiro, Hikaru Amamiya, Nobuo Sasai, Yoshikazu Naka, Hiroshi Takeda, Shogo Ito, Akira Kubota, Kiyokazu Matoba, Sachio Aoyagi, Fuyuki Minagawa, Masahiko Takai, Manabu Waseda, Mitsuo Obana
Publikováno v:
Journal of Diabetes Investigation. 3:503-509
(J Diabetes Invest, doi: 10.1111/j.2040-1124.2012.00221.x, 2012) Aims/Introduction: To determine the efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients after 3 months’ therapy. Materials and